Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection by Bassyouni, Iman H. et al.
Clin Chem Lab Med 2009;47(7):842–847  2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2009.189 2007/25
Article in press - uncorrected proof
Clinical significance of anti-cyclic citrullinated peptide
antibodies in Egyptian patients with chronic hepatitis C virus
genotype IV infection
Iman H. Bassyouni1, Yasser Ezzat2, Sherif
Hamdy3 and Roba M. Talaat4,*
1 Department of Rheumatology and Rehabilitation,
Faculty of Medicine, Cairo University, Egypt
2 Department of Rheumatology and Rehabilitation,
Faculty of Medicine, Fayoum University, Egypt
3 Department of Tropical Medicine, Faculty of
Medicine, Cairo University, Egypt
4 Department of Molecular Biology, Genetic
Engineering and Biotechnology Research Institute
(GEBRI), Minofia University, Egypt
Abstract
Background: Symmetric polyarthritis associated with
hepatitis C virus (HCV) infection frequently displays a
clinical picture like rheumatoid arthritis (RA). Antibod-
ies to cyclic citrullinated peptide (CCP) have high
specificity for the diagnosis of RA. This study exam-
ined the frequency and clinical significance of anti-
CCP antibodies in patients with chronic HCV infection,
with and without manifestations of joint involvement,
compared to RA patients.
Methods: Serum anti-CCP antibodies and rheumatoid
factor (RF) were evaluated in 30 patients with RA and
47 patients with chronic HCV infection. Of those with
HCV infection, 20 patients had chronic HCV infection
associated with articular involvement and 27 patients
had chronic HCV infection without any articular
involvement.
Results: Anti-CCP antibody level was positive in 70%
of RA patients, 8.5% of HCV-infected patients, and in
20% of HCV patients with articular manifestations. RF
was positive in 76% of RA patients and in 60% of HCV
patients with articular involvement. Cryoglobulins
were found in 29% of HCV-infected patients and in
16% of RA patients. Cryoglobulins were more fre-
quent among HCV patients with articular affection
(35%) compared to HCV patients without articular
affection (26%).
Conclusions: Although anti-CCP antibodies remain a
useful diagnostic tool for RA, their interpretation in
HCV-infected patients with arthritis should be applied
with caution. The possibility that those patients could
be prone to develop RA cannot be ruled out. Those
patients need careful clinical and radiological follow-
up. Further large-scale studies are warranted.
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Introduction
Infection with hepatitis C virus (HCV) remains a
severe life-threatening medical and public health
problem worldwide (1). The highest prevalence has
been reported from Egypt (2) where the main HCV
genotype is type IV, representing 90% of the Egyptian
HCV-infected population (3). It has emerged as a
major cause not only of liver disease, but also of
numerous extrahepatic conditions (4). Many rheu-
matologic manifestations were associated with HCV
infection, some of which are related to mixed cryo-
globulinemia, whose link to the HCV is now firmly
established (5).
Among the different clinical disorders associated
with HCV infection, articular involvement is a frequent
complication. HCV arthropathy frequently displays a
rheumatoid arthritis (RA)-like clinical picture, and
most patients with RA-like HCV related polyarthritis
fulfill the American College of Rheumatology (ACR)
criteria for RA (6). However, compared to RA, HCV-
associated arthritis is usually less severe and does not
cause joint deformities or rheumatoid nodules (7).
Because the classic clinical picture of RA is not entire-
ly helpful in the differential diagnosis, other diag-
nostic tools such as the detection of serological
abnormalities in sera of patients with RA, could be
helpful in differentiating between these disorders (8).
The detection of classic immunoglobulin M (IgM)
rheumatoid factor (RF) is of little utility as a diagnostic
tool for RA because a high percentage of patients with
chronic HCV infection display serum RF reactivity.
Also, the frequency of RF increases in patients with
articular involvement (9). During the last few years, a
variety of circulating non-RF antibodies have been
discovered and reported to have a potential diagnos-
tic value (10, 11). Anti-cyclic citrullinated peptide (anti-
CCP) antibodies are antibodies against synthetic
citrullinated peptides, and are specific markers of RA
(12). Anti-CCP antibodies are disease-specific and
sensitive markers for RA. In addition to their diagnos-
tic properties, anti-CCP antibodies have also been
shown to be good prognostic markers, as they help
predict the erosive or non-erosive progression of the
disease and anti-CCP antibodies are usually present
early in the course of disease (10). The present study
aimed to examine the frequency and clinical signifi-
cance of anti-CCP antibody in patients with chronic
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HCV infection, with and without manifestations of
joint involvement, compared to patients with RA.
Materials and methods
Patients
All patients enrolled in this study were referred to the Rheu-
matology and Rehabilitation Department and Tropical Med-
icine Department of El-Kasr El-Aini Hospital, Cairo
University, Egypt, from January 2006 to December 2007. All
investigations were done in accordance with the Cairo Uni-
versity, health and human Ethical Clearance Committee
guidelines for clinical researches. The local Ethics Commit-
tee approved the study protocol. All patients agreed to be
enrolled in this study.
All participants underwent a general and locomotor clini-
cal examination and gave a detailed history. Demographic,
clinical, immunochemical, virological, and liver histology
features were collected retrospectively for each patient. HCV
antibodies were measured using a 3rd generation enzyme
linked immunosorbent assay (ELISA) (Murex Biotech, Dart-
ford, UK) and confirmed using reverse transcriptase poly-
merase chain reaction (RT-PCR) (Promega Co., Madison, WI,
USA). Hepatitis B surface antigens (HBsAg) (Sorin Biomedica
Co., Saluggia, Italy) were measured using commercially
available kits. All patient groups were positive for HCV anti-
body and HCV-RNA.
Forty-seven HCV infected patients were enrolled. Two
groups of HCV patients were identified on the basis of the
presence of HCV-related arthropathy; Group I (20 patients
with articular involvement) and Group II (27 patients without
articular involvement). Patients with evidence of deformity,
erosions on radiographs or subcutaneous nodules were
excluded from the study. The control group for the diagnos-
tic reliability of the anti-CCP antibody was comprised of 30
patients with a definitive diagnosis of RA as per ACR criteria
(6). Controls were sero-negative for HCV.
Anti-CCP antibodies
Anti-CCP antibodies were measured using a commercial
anti-CCP ELISA kit (EUROIMMUN Medizinische Labordiag-
nostika AG, Lu¨beck, Germany) according to the manufactu-
rer’s instructions. A cut-off value of five relative units was
established, as recommended by the manufacturer’s proto-
col. The cut-off value was established by evaluating 419
patients with RA, 744 patients without RA and 400 healthy
controls. Values )5 units were considered positive for anti-
CCP immunoglobulin G (IgG) antibodies. We considered the
validation studies performed by the manufacturer to be suf-
ficient and to preclude the need for use of a healthy control
population in our study.
Rheumatoid factor (RF)
RF was determined using a latex fixation method. A suspen-
sion of uniform polystyrene particles sensitized in glycine
buffer with heat-altered human IgG (BD Diagnostic Systems,
Sparks, MD, USA) was incubated with progressive dilutions
of human sera in microtitre wells. After incubation, the
plates were visually inspected for agglutination.
Cryoglobulin detection
Venous blood was collected in a pre-warmed syringe and
stored at 378C until clotted. Serum was centrifuged at 378C
for 10 min at 2500 rpm (559 g), collected and stored at 48C
for 7 days. After isolation and washing, the components of
the cryoprecipitate were characterized by immunofixation
(13).
Radiographic assessment
Plain X-rays for both hands and wrists were obtained on
chronic HCV patients who had articular involvement at the
time of anti-CCP antibody analysis. If erosions were present,
the diagnosis of HCV related arthropathy was discarded, and
the patients were now considered to have RA with concom-
itant HCV infection. The radiographs of all patients were
reviewed by a senior rheumatologist.
Liver biopsy
Liver biopsy was performed whenever possible and
assessed histopathologically (14).
Statistical analysis
The Statistical Package for Social Sciences (SPSS) version
10 (LEAD Technology Inc., Charlotte, NC, USA) was used to
analyze patient data. Descriptive statistics included the mean
and standard deviation (SD) for quantitative variables, and
number and percentage for qualitative variables. Unpaired
t-test and Chi-square (x2), with Fisher exact test when appro-
priate, were used for statistical comparative analysis. A dif-
ference was considered to be statistically significant when
the (p) value was F0.05.
Results
Clinical and demographic data of studied
population
We enrolled 47 HCV-infected patients, ranging from
20 to 57 years of age, and 28 being female. All had
HCV genotype IV. Table 1 summarizes the demo-
graphic, clinical and serological characteristics of the
HCV-infected patients, with and without articular
involvement. Comparing HCV patients with articular
involvement to those without articular involvement,
no statistically significant differences were found
between any of the variables mentioned in the table.
Histological examination of hepatic biopsies showed
grading of activity from minimum to severe, with no
significant difference between patients with and with-
out arthritis.
Table 2 shows the demographic, articular charac-
teristics and erythrocyte sedimentation rate (ESR) lev-
els of patients with RA, and of HCV patients with
articular involvement. With respect to the pattern of
articular involvement in HCV patients with articular
involvement, all of them complained of polyarthral-
gias (20/20), three had mono-pauciarticular involve-
ment of large joints with predominance of the knee,
and nine had RA-like polyarthritis of the diarthroidal
joints of the hands.
Mean anti-CCP antibodies level in patients studied
The mean for anti-CCP antibodies was 3.00"5.64
U/mL (range 0.32–32.62) in the HCV group, while it
was 19.84"19.45 U/mL (range 1.3–75) in the RA
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Table 1 Clinical, demographic and laboratory characteristics of HCV patients with and without articular involvement.
Variable HCV with articular HCV without p-Value
involvement articular involvement
ns20 ns27
Age, yearsa 34.10"10.10 38.27"10.86 NS
Female/male 12/8 16/11 NS
Sicca syndromeb 6 (30) 4 (14) NS
Parathesiab 5 (25) 6 (22) NS
Myalgiasb 7 (35) 8 (29) NS
Vasculitisb 7 (35) 5 (18.5) NS
Raynaudsb 4 (20) 4 (14.8) NS
ESR, mm/1st ha 35.4"13.7 29.32"10.12 NS
AST, U/La 51.64"10.20 56.6"12.70 NS
ALT, U/La 51.09"13.60 45.8"19.50 NS
Serum albumina 3.82"0.47 3.54"1.92 NS
Creatinine, mmol/La 65.416"10.608 60.996"15.912 NS
Hemoglobin, g/La 127"11.3 132"15.2 NS
WBCs, =109/La 5.60"1.81 4.8"1.42 NS
PLT, =109/La 271.09"88.08 233.4"75.6 NS
aValues are mean"SD; bvalues are n (%); HCV, hepatitis C virus; ESR, erythrocyte sedimentation rate; AST, aspartate trans-
aminase; ALT, alanine transaminase; WBCs, white blood cells; PLT, platelets; NS, not significant.
Table 2 Demographic, articular characteristics and ESR lev-
els of patients with RA and HCV patients with articular
involvement.
Variable RA patients HCV with articular
ns30 involvement
ns20
Age, yearsa 39.2"10.6 34.10"10.10
Duration of articular 6.5"4.9 2.89"1.73
manifestations, yearsa
Morning stiffness )1 hb 22 (73) 9 (45)
Arthritis of 3 or more 28 (93.3) 9 (45)
joint areasb
Symmetric arthritisb 28 (93.3) 7 (35)
Subcutaneous nodulesb 3 (10) 0
Deformityb 14 (46) 0
Radiological erosionsb 11 (36) 0
ESR, mm/1st ha 42"24 35.4"13.7
aValues are mean"SD; bvalues are n (%); ESR, erythrocyte
sedimentation rate; RA, rheumatoid arthritis; HCV, hepatitis
C virus.
Figure 1 Serum anti-CCP antibody levels in the various
disease categories.
Data are presented as box plots with lines inside the box
representing medians, boxes representing the 25th and 75th
percentiles and the lines outside the boxes indicating the
10th and 90th percentiles.
group (p-0.001). Mean levels were highly significant
(p-0.001) when comparing the RA group to the HCV
patients with arthritis (5.22"8.13 U/mL). In addition,
a significant difference (p-0.05) was found when
comparing mean anti-CCP antibodies in patients with
HCV and articular involvement to those without artic-
ular involvement (1.36"1.18 U/mL). Figure 1 shows
the anti-CCP antibody levels for the various disease
categories.
Prevalence of anti-CCP antibodies, RF, and
cryoglobulins in studied patients
Anti-CCP antibodies were positive in only four
patients, representing 8.5% of the HCV-infected
group. Three patients tested positive for both anti-
CCP antibodies and RF, and had symmetric polyar-
thritis (RA-like). Their ages ranged from 36 to 52 years
and their duration of disease (with respect to arthritis)
ranged from 4 to 6 years. Table 3 summarizes the
characteristics of HCV patients with elevated anti-CCP
antibody levels.
The prevalence of anti-CCP antibody positive
patients increased to 20% (4/20) in patients having
chronic HCV and articular involvement, while the
prevalence was zero in chronic HCV patients without
articular involvement. This finding was statistically
significant (p-0.05). Anti-CCP antibody level was pos-
itive in 70% of the RA patients. A significant difference
(p-0.001) was found between the frequency of anti-
CCP antibodies between the RA group and chronic
HCV patients with arthritis. RF was positive in 76% of
RA patients, whereas it was found in 60% of patients
affected by HCV with articular involvement (12/20);
this difference was statistically insignificant. However,
a statistically significant difference (p-0.05) was
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Table 3 Characteristic of HCV patients with elevated anti-CCP antibody levels.
Patient no. 2 7 8 14
Age, years 36 43 52 43
Sex M F F F
Arthralgia Y Y Y Y
Duration of arthritis, years 4 6 4 4
RA like arthritis Y N Y Y
Pauciarticular arthritis N Y N N
Sicca syndrome N Y Y Y
Parathesia N N Y N
Myalgia Y N N Y
Vasculitis Y N N Y
Raynauds phenomenon Y Y N N
ALT, U/L 52 34 79 46
AST, U/L 45 61 54 59
ESR, mm/1st h 20 48 35 52
RF Y N Y Y
Cryoglobulin N Y Y N
Anti-CCP antibodies 10.09 11.77 32.62 20.30
Y, yes; N, no; M, male; F, female; ALT, alanine transaminase; AST, aspartate transaminase; ESR, erythrocyte sedimentation
rate; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptides.
Figure 2 Prevalence of anti-CCP antibody, RF and cryoglobulins in RA and HCV-infected patients.
(a) Statistically significant from HCV patients without articular involvement. (b) Statistically significant from RA patients.
*p-0.05; ***p-0.001.
found when comparing the frequency of RF in HCV
patients with arthritis to those without arthritis. Cryo-
globulins were found in 14 of the chronic HCV-
infected patients (29%), and in five patients with RA
(16%). Although cryoglobulins were more frequent
among chronic HCV patients with articular affection
(35%) compared to those without affection (26%), the
difference was not statistically significant. Figure 2
shows the prevalence of anti-CCP antibodies, RF and
cryoglobulins in RA and HCV-infected patients.
Discussion
The articular manifestations of chronic HCV and RA
may be very similar, and the prevalence of RF is the
same in the two conditions (15). Numerous studies
have corroborated the high specificity ()95%) of the
anti-CCP assay for the diagnosis of RA, and its asso-
ciation with erosive inflammatory joint disease has
added to the prognostic value of anti-CCP antibodies
(10). However, the control sera used to assess the
specificity of this assay were derived primarily from
normal subjects and patients with a wide variety of
rheumatic diseases; patients with HCV were not well-
represented (10). Thus, the objective of our study was
to assess the presence of anti-CCP antibodies in
patients with HCV infection, with and without mani-
festations of joint involvement, in comparison to
patients with RA.
Van Boekel et al. (16) concluded that anti-CCP anti-
bodies had the most value for diagnosis of RA.
Despite the high specificity described for the anti-CCP
antibody test, four (i.e., 8.5%) patients from the HCV-
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infected group were positive for anti-CCP antibodies.
The prevalence increased to 20% (4/20) when consid-
ering only HCV with articular manifestations, while
anti-CCP antibodies were absent in patients without
articular involvement. On the other hand, the frequen-
cy of cryoglobulins and RF was comparable between
HCV patients and RA patients in our patient cohort.
The previously reported prevalence of anti-CCP anti-
bodies among patients with HCV ranged from none
to 9%, depending on the population studied and
whether it was associated with cryoglobinemia
(17–20). For example, Se`ne et al. (17) found anti-CCP
antibodies positive in 5.7% of HCV-infected patients
with arthralgia, whereas they were present in 78% of
patients with RA. Another study detected anti-CCP
antibodies in 6.9% of patients with mixed cryoglobu-
lins (18). Similarly, Liu et al. (19) detected a significant
number of HCV-infected patients with RF and cryoglo-
bulinemia who were also positive for anti-CCP anti-
bodies. On the other hand, Girelli and colleagues (20)
reported that RF was present in 91% of patients with
RA and 86% of the patients who had HCV-related
arthritis, whereas anti-CCP antibodies were seen in
71% and 0% of patients, respectively.
Although our study reconfirms the association of
anti-CCP antibodies with RA (present in 70%), the
number of our patients with HCV arthritis who have
anti-CCP antibodies is greater than would be expected
with respect to the high specificity of the test (16). The
high prevalence of anti-CCP antibodies might reflect
ethnic differences or different genotypes of the HCV
virus (i.e., IV) found in our patients, which differ com-
pared to patients evaluated in other studies. It has
been suggested that chronic HCV with genotypes IV
through IX may exhibit epidemiologic, clinical, and
treatment outcomes different from those for geno-
types I, II, or III (21).
The synthesis of citrullinated proteins has been
shown to increase as a result of both apoptosis and
inflammation-induced cellular death (necroinflamma-
tion). This suggests that this process is inflammation-
dependent rather than disease-dependent (22, 23).
Moreover, the presence of anti-CCP antibody has
been reported, in low prevalence, in association with
systemic lupus erythematosus, systemic sclerosis,
polymyositis (24), Sjo¨gren syndrome (25) and psori-
asis (26, 27). Recently, a relatively high percentage
(9%) of patients with anti-CCP antibody was detected
in a large group of individuals with autoimmune hep-
atitis, but without apparent overlap with RA (28).
The basis for the association of anti-CCP antibodies
with HCV arthritis in our study of patients with chronic
HCV is speculative. It might be a part of the height-
ened immune reactive state characteristic of HCV
infection, in which epitope spread and molecular
mimicry result in multiple serological reactivities, or
concurrent immune disorders with the production of
a wide range of autoantibodies produced against
liver- and non-liver-specific autoantigens (29–31).
Extravascular citrullinated fibrin is one of the citrul-
linated proteins that trigger production of anti-CCP
antibodies in patients with RA. HCV infection can
cause chronic liver injury with the release of large
amounts of fibrin and fibrin fragments that can be
citrullinated. These citrullinated antigens may then
activate CD4q T helper cells and stimulate production
of anti-CCP (30). The presence of mRNA of peptidyl-
arginine deiminase (PAD) enzyme in fetal liver, with
the occurrence of citrullination processes within this
organ, and subsequent release of liver-derived sub-
strates could lead to the generation anti-CCP anti-
bodies (32).
To summarize, our results suggest that anti-CCP
antibodies may be present in HCV patients presenting
with articular manifestations, but must be interpreted
with caution. However, it is possible that patients with
anti-CCP antibody could be prone to develop RA. It is
well known that anti-CCP antibodies can be present
years before the first sign of RA. Careful clinical and
radiological follow-up is required to confirm the
absence of evolution to RA in anti-CCP antibody
positive patients. Further large-scale studies are
warranted.
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